Acquisition Will Bolster Quintiles' Expertise in Health-Information Analytics Services and Create Foundation for Expanded Services Suite
RESEARCH TRIANGLE PARK, N.C. – May 12, 2014 – As part of its continued efforts to strengthen and expand its service capabilities across the healthcare continuum, Quintiles today announced that it has signed an agreement to acquire Encore Health Resources (Encore). Encore is a leader in the health-information analytics and technology services industry focused on healthcare providers. Through its consulting services and solutions, Encore assists customers with a wide range of strategy, advisory, implementation, process-redesign, optimization, analytics and performance-improvement initiatives.
Founded in 2009, Encore has more than 300 employees located throughout North America, including approximately 250 consultants. Its primary business is focused on implementation and advisory services around electronic health records (EHR). The addition of these capabilities will enhance Quintiles' EHR expertise, which is becoming increasingly important as biopharmaceutical customers, payers and providers focus on measuring outcomes based on real-world performance in terms of clinical effectiveness and value.
"Today's announcement signifies the increasing importance of leveraging EHR and real-world information to inform our customers and improve their probability of success," said Tom Pike, chief executive officer at Quintiles. "Encore has significant EHR expertise, strong relationships with many large U.S. provider networks and academic medical centers as well as experienced consultants, proven tools, and methodologies. It will be a key strategic addition for our business that will extend our services suite and allow us to work with Encore to strengthen its provider-focused solutions."
Biopharmaceutical companies are increasingly interested in the "real-world" outcomes associated with their medicines to enable optimal market access. Encore's expertise with hospitals and hospital information will help Quintiles extend its service offerings meaningfully for biopharmaceutical companies.
By joining Quintiles, Encore will be able to leverage Quintiles' breadth and depth of capabilities as well as its global scale to accelerate Encore's vision of enhancing clinical outcomes through data-driven performance improvement. Additionally, Encore can utilize the expertise of Quintiles' 950 medical doctors, 900 Ph.D.'s, as well as its nurse educators and world-class biostatisticians to help hospitals and providers solve their most pressing population health challenges.
"Today is the beginning of an exciting new chapter for Encore," said Dana Sellers, chief executive officer, Encore. "Encore was founded with a focus on driving value through data to improve performance and clinical outcomes. I believe that this focus and our vision for the future align well with Quintiles. We will be joining a global leader, and we look forward to working together to help deliver further advancements in healthcare."
The transaction, which is subject to standard and customary closing conditions, is expected to close later this quarter. Upon completion of this transaction, Encore will join Quintiles' Integrated Healthcare Services segment and be known as "Encore, A Quintiles Company."
Financial terms of the transaction are not being disclosed. The acquisition is not expected to have a material impact on Quintiles' 2014 earnings per share.
Quintiles (NYSE: Q) is the world's largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 29,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect, among other things, Quintiles' current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause Quintiles' actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "should," "guidance," "targets," "will" and the negative thereof and similar words and expressions are intended to identify forward-looking statements. These statements are subject to risks, uncertainties and assumptions, including our ability to complete, integrate and achieve our intended objectives with respect to the proposed acquisition of Encore and those described under the section entitled "Risk Factors" in Quintiles' annual report on Form 10-K for the fiscal year ended December 31, 2013, filed with the SEC on February 13, 2014, as such factors may be updated from time to time in Quintiles' periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Quintiles' filings with the SEC. Unless legally required, Quintiles assumes no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.
Phil Bridges, Media Relations ([email protected])
Karl Deonanan, Investor Relations ([email protected])